Analysing criteria for price and reimbursement of orphan drugs in Spain.

CONCLUSIONS: It remains challenging to establish which are the driving criteria for pricing and reimbursement approval of orphan drugs in Spain. Further research should be done including other variables that might influence the pricing and reimbursement final decision in Spain. PMID: 31276443 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31276443?dopt=Abstract

Source: Farmacia Hospitalaria - June 30, 2019 Category: Drugs & Pharmacology Authors: Badia X, Gil A, Poveda-Andrés JL, Shepherd J, Tort M Tags: Farm Hosp Source Type: research

More News: Clinical Trials | Drugs & Pharmacology | Spain Health